SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Goldman Sachs Starts Sage Therapeutics (SAGE) at Buy
May 15, 2015 7:02 AM EDTGoldman Sachs initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $80.00.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $58.29 yesterday.
... MoreSage Therapeutics (SAGE) PT Raised to $70 at Leerink Partners as New Data Corroborates Prior Promising Results
May 14, 2015 11:03 AM EDTLeerink Partners analyst Paul Matteis reiterated an Outperform rating and boosted his price target on Sage Therapeutics (NASDAQ: SAGE) to $70.00 (from $54.00) after final phase I/II SAGE-457 data corroborates prior promising results.
Matteis commented, "This morning SAGE reported final... More
SAGE Therapeutics (SAGE) Misses Q1 EPS by 17c
May 14, 2015 6:33 AM EDTSAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($0.66), $0.17 worse than the analyst estimate of ($0.49).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
... More